Lymphoma physicians from John Theurer Cancer Center comment on the use of CAR T-cell therapy in large B-cell lymphoma and the implications of clinical trial data in this setting.
Zanubrutinib Combo Improves ORR Vs Obinutuzumab in Follicular Lymphoma
October 24th 2023The primary end point of overall response rate is met in the phase 2 ROSEWOOD study of patients with relapsed/refractory follicular lymphoma receiving zanubrutinib plus obinutuzumab vs obinutuzumab monotherapy.